Fort Detrick scientist up for Heyman Service to America Medal; Fina Biosolutions to develop and manufacture pneumococcal vax in China;

> Scientists have been carrying out tests of a new universal flu vaccine on elderly members of the population in Winnipeg, Canada, for the past 5 weeks. Story

> Art Friedlander, the Fort Detrick, MD, scientist who improved the anthrax vaccine after 2001 attacks in the U.S., is a Heyman Service to America Medal finalist. News

> Alnylam Pharmaceuticals ($ALNY) announced positive preclinical results in applying its RNAi technology to cancer vaccines. Article

> Fina Biosolutions signed a licensing deal with Chengdu Institute of Biological Products to develop and manufacture a pneumococcal conjugate vaccine in China. Item

> Scientists report new insights into how a family of rare, highly potent antibodies bind to HIV and neutralize it. More

> The European Medicines Agency accepted the filing of Dynavax Technologies' marketing authorization application for the hepatitis B vaccine drug Heplisav. Story

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.